Mateos, M. V., Rigaudeau, S., Basu, S., Spicka, I., Schots, R., Wrobel, T., Cook, G., Beksac, M., Gries, K. S., Kudva, A., Tromp, B., Van Rampelbergh, R., Pei, H., Wroblewski, S., Carson, R., Delioukina, M., & White, D. (2023). Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma. Journal of Oncology Pharmacy Practice, 29(5), 1172-1177. https://doi.org/10.1177/10781552221103551
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma. / Mateos, Maria Victoria; Rigaudeau, Sophie; Basu, Supratik et al.
In:
Journal of Oncology Pharmacy Practice, Vol. 29, No. 5, 07.2023, p. 1172-1177.
Research output: Contribution to journal › Article › peer-review
Mateos, MV, Rigaudeau, S, Basu, S, Spicka, I, Schots, R, Wrobel, T, Cook, G, Beksac, M, Gries, KS, Kudva, A, Tromp, B, Van Rampelbergh, R, Pei, H, Wroblewski, S, Carson, R, Delioukina, M & White, D 2023, 'Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma', Journal of Oncology Pharmacy Practice, vol. 29, no. 5, pp. 1172-1177. https://doi.org/10.1177/10781552221103551
Mateos MV, Rigaudeau S, Basu S, Spicka I, Schots R, Wrobel T et al. Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma. Journal of Oncology Pharmacy Practice. 2023 Jul;29(5):1172-1177. doi: 10.1177/10781552221103551
Mateos, Maria Victoria ; Rigaudeau, Sophie ; Basu, Supratik et al. / Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma. In: Journal of Oncology Pharmacy Practice. 2023 ; Vol. 29, No. 5. pp. 1172-1177.
@article{c177307a00a245ac8b34e3a3a61bb2dc,
title = "Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma",
keywords = "Multiple myeloma, daratumumab, intravenous, subcutaneous, transplant-ineligible",
author = "Mateos, {Maria Victoria} and Sophie Rigaudeau and Supratik Basu and Ivan Spicka and Rik Schots and Tomasz Wrobel and Gordon Cook and Meral Beksac and Gries, {Katharine S.} and Anupa Kudva and Brenda Tromp and {Van Rampelbergh}, Rian and Huiling Pei and Susan Wroblewski and Robin Carson and Maria Delioukina and Darrell White",
note = "Publisher Copyright: {\textcopyright} The Author(s) 2022.",
year = "2023",
month = jul,
doi = "10.1177/10781552221103551",
language = "English",
volume = "29",
pages = "1172--1177",
journal = "Journal of Oncology Pharmacy Practice",
issn = "1078-1552",
publisher = "SAGE Publications Ltd",
number = "5",
}
TY - JOUR
T1 - Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma
AU - Mateos, Maria Victoria
AU - Rigaudeau, Sophie
AU - Basu, Supratik
AU - Spicka, Ivan
AU - Schots, Rik
AU - Wrobel, Tomasz
AU - Cook, Gordon
AU - Beksac, Meral
AU - Gries, Katharine S.
AU - Kudva, Anupa
AU - Tromp, Brenda
AU - Van Rampelbergh, Rian
AU - Pei, Huiling
AU - Wroblewski, Susan
AU - Carson, Robin
AU - Delioukina, Maria
AU - White, Darrell
N1 - Publisher Copyright:
© The Author(s) 2022.
PY - 2023/7
Y1 - 2023/7
KW - Multiple myeloma
KW - daratumumab
KW - intravenous
KW - subcutaneous
KW - transplant-ineligible
UR - http://www.scopus.com/inward/record.url?scp=85138338424&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138338424&partnerID=8YFLogxK
U2 - 10.1177/10781552221103551
DO - 10.1177/10781552221103551
M3 - Article
C2 - 36067063
AN - SCOPUS:85138338424
SN - 1078-1552
VL - 29
SP - 1172
EP - 1177
JO - Journal of Oncology Pharmacy Practice
JF - Journal of Oncology Pharmacy Practice
IS - 5
ER -